Heidelberg Pharma AG

Stocks

HPHA

DE000A11QVV0

Market Closed - Xetra 11:35:29 2026-08-19 EDT			5-day change	1st Jan Change
2.510 ^EUR	-0.79%		-1.57%	+1.21%

07-15	Heidelberg Pharma AG Reports Earnings Results for the Half Year Ended May 31, 2026	CI
06-23	Heidelberg Pharma Ag Approves the Election of Mr. Jack Yefei Ling as New Member of the Supervisory Board	CI

Transcript : Heidelberg Pharma AG - Special Call

Published on 11/11/2025 at 12:35 pm EST - Modified on 11/11/2025 at 07:05 pm EST

S&P Capital IQ

Presenter Speech
Andras Strassz (Executives)

Hi, and very welcome, everybody, who joined our webinar today. My name is Andras Strassz. I'm the Chief Medical Officer of Heidelberg Pharma. And today, we

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Full unlimited browsing across the entire site

Access to all the news and all the data

Access to US, EUROPE AND ASIA Portfolios

Zero Ads for a completely uninterrupted reading experience

Pro Tools: Expert insights, Expert Screeners, historical financial data and reports, thematic lists, transcripts...

Latest news about Heidelberg Pharma AG

07-15	Heidelberg Pharma AG Reports Earnings Results for the Half Year Ended May 31, 2026	CI
06-23	Heidelberg Pharma Ag Approves the Election of Mr. Jack Yefei Ling as New Member of the Supervisory Board	CI
04-29	Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 28, 2026	CI
04-17	Heidelberg Pharma AG Announces Chief Financial Officer Changes	CI
04-09	Heidelberg Pharma Sets Dose for Mid-stage Trial of Multiple Myeloma Drug Candidate	MT
04-09	Heidelberg Pharma AG Determines Recommended Dose for Phase II Trial with ADC Candidate HDP-101	CI
04-04	Heidelberg Pharma AG Presents Data from Its ADC Technology Platform At AACR Annual Meeting	CI
03-31	Heidelberg Pharma AG, 2025 Earnings Call, Mar 26, 2026
03-26	Heidelberg Pharma AG Reports Earnings Results for the Full Year Ended November 30, 2025	CI
03-26	Heidelberg Pharma AG Provides Earnings Guidance for the Fiscal Year 2026	CI
03-18	Heidelberg Pharma Set to Get Milestone Payment for Plasma Cell Disorders Treatment Clinical Study	MT
03-18	Heidelberg Pharma AG Receives Milestone Payment for Clinical Study with HDP-101 in China	CI
03-06	Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement	RE
11-25	Heidelberg Pharma Names New CEO	MT
11-24	Heidelberg Pharma AG Announces Chief Executive Officer Changes, Effective 24 November 2025	CI